Post-Exertional Malaise Is Associated with Hypermetabolism, Hypoacetylation and Purine Metabolism Deregulation in ME/CFS Cases, 2019, McGregor et al

Sorry you're feeling so crap – I hope it improves soon.

To be honest, I buy whatever's on sale at the time. My latest are from MyProtein, called Essential BCAA, and I take the dose suggested on the bottle.

They're not a cure for pushing too hard, but for me they reliably reduce the symptoms of PEM from overdoing things a bit. Normally, I'd wake up with a swollen throat and body-wide weakness, which would last a couple of days. If I start BCAAs as soon as I realise I've gone over my limit, this subsides within an hour or so of waking. I still need to rest just as much, but I don't feel really ill in the way I usually would.

They seem to work well for some folk, but I don't think it'd be a good strategy to use them as a way to exceed your envelope on a regular basis. I use them when I hit the wall by accident or unexpectedly, and it hasn't led to any crashes in the year or so since I started them.

Thanks for this info @Kitty.

It sounds like I’ve been taking them differently to you.

I started out on a daily dose as per the bottle, which was 2 tablets. Weirdly I felt too wired and I reduced the dosage to half. I was taking this as well as a vegan protein shake and I really felt it made me feel more ‘normal’ and able to get through the daily tasks without too much trouble.

In fact I was feeling so ‘normal’ I went to a wedding, drank a bucket full of rum punch and danced all night. Then I went home, vomited, had a dreadful hangover and I haven’t felt alright since! That was 5 weeks ago.

I think I’m just in a bad crash but I haven’t actually had one for a long time.

All the best and thanks again
 
Lordy, I don't even understand the basics presented in that thread. I'm glad they took the time to do this, though.

What does this bit mean? In the 3rd tweet in the thread:

It would appear short burst activity may be more beneficial.

Is this referring to the patient's activity (i.e. pacing), or is it referring to activity in bodily systems that we don't really have any control over?
 
I find the information hard to interpret too, as it requires an understanding of biochemistry that I lack entirely. But I think this sentence is important (my bolding):

Reductions in the purine metabolite, hypoxanthine, were also found in the serum metabolomes of the females in first morning fasted samples [2] and potentially indicated reductions in the ability to produce ATP.
May be a ridiculous question but If the purine metabolite is reduced does that mean there’s also more purine still going round in the system? On my postage stamp understanding it is the purine that causes the problems & pain in gout. Could this be causing pain in ME.
 
Last edited:
I'd like to reopen the discussion on this study because it shows more significance than usual CFS studies thanks to their PEM differentiation.

As a first note, there might be a measurement bias regarding the measured purine metabolites in the urine. Here are two quotes from their original study that has been published in 2015 (10.1007/s11306-015-0816-5). The new study used the same collection methods.

Urine was collected upon rising by each subject and stored at 4 C and within 6 h a blood sample was then taken by venipuncture into BD Vacutainer blood collection tubes.

All urinary absolute concentration metabolites were decreased in ME/CFS patients: acetate; alanine; formate; pyruvate; and serine. Eight metabolites were significantly altered within the relative abundance dataset for urine. These include the five that were decreased in ME/CFS in the absolute concentration data, along with decreased valine and increased allantoin and creatinine.

Creatinine has been used to standardize urinary metabolite concentrations to account for variations in urinary accumulation and dilution factors. In this instance we deemed it an inappropriate method as creatinine was trending towards a significant decrease within the absolute concentration blood data of ME/CFS patients (Fig. 3a). In this study when the urinary data was normalized to urinary creatinine all metabolites were significantly altered, which we concluded was an artificial result (Fig. 4a). To remove the influence of dilution factor on both the urine and the blood we normalized each sample to the total metabolite concentration, therefore producing relative abundance data.

They should have switched to 24h urine since this is the only other way of normalization that allows a total quantification with blood levels. I don't think that hyperfiltration is untypical for CFS, so this is a general issue when CFS studies try to analyze single urine samples. The only value of the result is the concentration relative to each other.
 
I'd like to reopen the discussion on this study because it shows more significance than usual CFS studies thanks to their PEM differentiation.
This is an interesting paper and thread!

They should have switched to 24h urine since this is the only other way of normalization that allows a total quantification with blood levels. I don't think that hyperfiltration is untypical for CFS, so this is a general issue when CFS studies try to analyze single urine samples. The only value of the result is the concentration relative to each other.
This seems to have been a retrospective analysis of data they had gathered over previous years.
All subjects signed consent forms. This study was approved by the University of Melbourne human research ethics committee (HREC# 0723086, 2010) and the first specimens were collected on 23 September 2010.

This is the talk Neil McGregor gave in 2019 at the Australian ME/CFS Conference. Worth listening to if you have not already. The paper was published shortly after.
https://mecfsconference.org.au/videos/neil-mcgregor/
 
This seems to have been a retrospective analysis of data they had gathered over previous years.

I mistakenly assumed that the second study referred to an extended sample set and that the first one was on data from 2010 only by how they mentioned "second urine sample" and "first specimens".

I'll eventually read these papers and come back with some more information and references. Especially the comments here drew my attention and I'd like to elaborate on some of them. At least some of the open questions I could explain by data that has recently been published and would fit into my COMT hypothesis. Where I'm still not sure how the altered lipid metabolism fits into this.

For mannitol in particular, I can think of three possibilities at the moment. It interacts with the fructose metabolism. One possibility would hence by an aldolase defect, which also affects glycolysis, ATP recycling, and phosphorylation severely, as well as it fits into the emerging Diabetes 3 hypothesis, which basically classifies diseases of glycolysis-dependant neuropathy (in my words). If this was the case, and the aldolase defect was hereditary, the DecodeME study could identify it. If this was the case, it's probably not a critical hereditary disease like HFI but rather like hereditary lactose intolerance - a silent condition that requires certain triggers like an infection and if untreated will still become more and more severe. Unknown compound heterozygote mutations are difficult to filter and identify, though. It could be overlooked in a study because not every patient will have the same mutations.

A second explanation would be that it is the overburdening of glycolysis that also overburdens the fructose metabolism indirectly by their shared metabolic pathways. I have to look into this one first to confirm the possibility.

The third explanation fits into my COMT/methylation hypothesis where NADPH-cycle-dysbalance is induced in multiple ways. Previous research has already linked this with xanthine oxidase as well, which was one point previously mentioned here (10.1096/fasebj.26.1_supplement.678.10). But I still have to look into this one. Specific immunological signals can affect xanthine oxidase to create ROS, which normally is a physiological reaction (10.1155/2016/3527579). Overall, the sample size of NADs in CFS patients is quite limited unlike the data around the methionine metabolism.
 
Last edited:
Back
Top Bottom